Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$211.63 +0.6%	$196.10	$163.81 ▼ $218.66	$371.68B	0.53	4.21 million shs	4.33 million shs
LLY Eli Lilly and Company	$734.57 +0.3%	$747.03	$623.78 ▼ $969.65	$693.36B	0.47	6.61 million shs	3.22 million shs
LVS Las Vegas Sands	$57.03 -1.0%	$51.41	$30.18 ▼ $58.05	$39.56B	1.04	3.59 million shs	5.16 million shs
PFE Pfizer	$24.94 +0.7%	$24.82	$20.92 ▼ $30.43	$140.77B	0.55	40.15 million shs	44.25 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.66%	+1.49%	+8.43%	+12.99%	+7.80%
LLY Eli Lilly and Company	+0.29%	-0.05%	-3.53%	-4.20%	-23.48%
LVS Las Vegas Sands	-1.07%	+1.38%	+9.07%	+37.92%	+46.27%
PFE Pfizer	+0.80%	-0.12%	+6.16%	+6.47%	-14.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.6443 of 5 stars	2.5	3.0	3.3	3.9	2.8	2.5	1.9
LLY Eli Lilly and Company	5 of 5 stars	4.3	3.0	3.3	4.0	2.6	3.3	3.8
LVS Las Vegas Sands	3.635 of 5 stars	2.4	3.0	2.5	0.8	2.4	0.0	1.9
PFE Pfizer	4.8093 of 5 stars	2.2	3.0	4.2	4.5	2.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$214.95	1.57% Upside
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.35% Upside
LVS Las Vegas Sands	2.75	Moderate Buy	$59.00	3.45% Upside
PFE Pfizer	2.39	Hold	$28.12	12.76% Upside

Current Analyst Ratings Breakdown

Latest LLY, ABBV, PFE, and LVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	LVS Las Vegas Sands	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$55.00 ➝ $65.00
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/25/2025	ABBV AbbVie	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/12/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$231.00
8/11/2025	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.64	$15.02 per share	14.09	($0.08) per share	-2,645.38
LLY Eli Lilly and Company	$45.04B	15.44	$14.27 per share	51.47	$19.39 per share	37.88
LVS Las Vegas Sands	$11.30B	3.47	$4.23 per share	13.49	$3.32 per share	17.18
PFE Pfizer	$63.63B	2.23	$4.40 per share	5.67	$15.66 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.10	100.78	15.14	1.35	6.45%	699.66%	13.64%	10/29/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	48.01	23.60	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
LVS Las Vegas Sands	$1.45B	$1.98	28.80	19.53	2.18	12.16%	55.37%	7.89%	10/22/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.26	8.23	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest LLY, ABBV, PFE, and LVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/31/2025	Q2 2025	ABBV AbbVie	$3.24	$2.97	-$0.27	$0.52	$14.93 billion	$15.42 billion
7/23/2025	Q2 2025	LVS Las Vegas Sands	$0.53	$0.79	+$0.26	$0.66	$2.83 billion	$3.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.10%	N/A	312.38%	53 Years
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years
LVS Las Vegas Sands	$1.00	1.75%	N/A	50.51%	2 Years
PFE Pfizer	$1.72	6.90%	N/A	91.49%	16 Years

Latest LLY, ABBV, PFE, and LVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
7/23/2025	LVS Las Vegas Sands	quarterly	$0.25	2%	8/5/2025	8/5/2025	8/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.74	0.61
LLY Eli Lilly and Company	1.86	1.28	1.00
LVS Las Vegas Sands	6.53	1.22	1.21
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
LVS Las Vegas Sands	39.16%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
LLY Eli Lilly and Company	0.14%
LVS Las Vegas Sands	1.20%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.77 billion	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.13 million	Optionable
LVS Las Vegas Sands	40,300	686.45 million	678.22 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

LLY, ABBV, PFE, and LVS Headlines

Recent News About These Companies

Healthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse

...

5 hours ago | marketbeat.com

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

September 2 at 5:32 PM | zacks.com

Olema stock jumps after new clinical trial collaboration with Pfizer

September 2 at 1:13 PM | investing.com

Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating

September 2 at 1:13 PM | seekingalpha.com

Is Pfizer Stock Underperforming the Nasdaq?

September 2 at 9:11 AM | barchart.com

Our Top September Stocks Yielding 6% and More Deliver Huge Passive Income

September 2 at 8:43 AM | 247wallst.com

Olema Pharmaceuticals Partners with Pfizer for New Trial

September 2 at 7:31 AM | tipranks.com

Pfizer, Moderna in focus as Trump demands answers on COVID success

September 2 at 7:31 AM | seekingalpha.com

Olema Pharmaceuticals and Pfizer Collaborate on Clinical Trial for Palazestrant-Atirmociclib Combination in Metastatic Breast Cancer

September 2 at 7:30 AM | quiverquant.comQ

First Financial Bankshares Inc Buys 18,696 Shares of Pfizer Inc. $PFE

September 2 at 7:21 AM | marketbeat.com

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

September 2 at 7:00 AM | globenewswire.com

Chiron Capital Management LLC Has $1.90 Million Stock Position in Pfizer Inc. $PFE

September 2 at 6:39 AM | marketbeat.com

First Manhattan CO. LLC. Sells 32,967 Shares of Pfizer Inc. $PFE

September 2 at 6:18 AM | marketbeat.com

Focus Partners Advisor Solutions LLC Purchases 20,225 Shares of Pfizer Inc. $PFE

September 2 at 6:08 AM | marketbeat.com

Flputnam Investment Management Co. Lowers Holdings in Pfizer Inc. $PFE

September 2 at 6:00 AM | marketbeat.com

Graham Capital Management L.P. Takes Position in Pfizer Inc. $PFE

September 2 at 5:58 AM | marketbeat.com

Vident Advisory LLC Raises Stake in Pfizer Inc. $PFE

September 2 at 5:14 AM | marketbeat.com

Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide

September 2 at 3:51 AM | insidermonkey.com

Trump Demands Pfizer, Other Covid Drug Makers To 'Justify The Success,' Show Their Results Amid New FDA Restrictions

September 2 at 3:50 AM | benzinga.com

A Look at Pfizer’s Valuation After FDA Approval of Next-Gen COVID Vaccine for Older Adults and High-Risk Groups

September 1 at 5:09 PM | finance.yahoo.com

Pfizer's Golden Cross Signals Strength: How to Play the Stock

September 1 at 1:01 PM | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, ABBV, PFE, and LVS Company Descriptions

AbbVie NYSE:ABBV

$211.63 +1.23 (+0.58%)

Closing price 09/2/2025 03:59 PM Eastern

Extended Trading

$211.65 +0.02 (+0.01%)

As of 09/2/2025 07:55 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$734.57 +1.99 (+0.27%)

Closing price 09/2/2025 03:59 PM Eastern

Extended Trading

$733.80 -0.77 (-0.10%)

As of 09/2/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Las Vegas Sands NYSE:LVS

$57.03 -0.60 (-1.04%)

Closing price 09/2/2025 03:59 PM Eastern

Extended Trading

$57.05 +0.02 (+0.03%)

As of 09/2/2025 07:56 PM Eastern

Las Vegas Sands Corp., together with its subsidiaries, develops, owns, and operates integrated resorts in Macao and Singapore. It owns and operates The Venetian Macao Resort Hotel, the Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Hotel Macao, Cotai Strip, and the Sands Macao in Macao, the People's Republic of China; and Marina Bay Sands in Singapore. The company's integrated resorts feature accommodations, gaming, entertainment and retail malls, convention and exhibition facilities, celebrity chef restaurants, and other amenities. Las Vegas Sands Corp. was founded in 1988 and is based in Las Vegas, Nevada.

Pfizer NYSE:PFE

$24.94 +0.18 (+0.71%)

Closing price 09/2/2025 03:59 PM Eastern

Extended Trading

$24.95 +0.01 (+0.06%)

As of 09/2/2025 07:58 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time